Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefitinib plus gemcitabine in metastatic pancreatic cancer refractory to primary treatment
IRCT20240721062502N3Phase 2Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of gefitinib and gemcitabine in pancreatic cancer (PC), sponsored by Shiraz University of Medical Sciences. Started Jul 2025; status: completed.
02
Drugs
gefitinibgemcitabine
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on IRCT20240721062502N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240721062502N3.